By
From the * Commissariat à l'Energie Atomique, Département d'Ingénierie et d'Etudes des Protéines (DIEP)
C.E. Saclay, Gif-Sur-Yvette cedex, France; and the Institut National de la Santé et de la Recherche
Médicale U255, Laboratoire d'Immunologie Cellulaire et Clinique, Institut Curie, Paris cedex 05, France
![]() |
Abstract |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Using a snake toxin as a proteic antigen (Ag), two murine toxin-specific monoclonal antibodies (mAbs), splenocytes, and two murine Ag-specific T cell hybridomas, we showed that soluble protein A (SpA) from Staphylococcus aureus and protein G from Streptococcus subspecies, two Ig binding proteins (IBPs), not only abolish the capacity of the mAbs to decrease Ag presentation but also increase Ag presentation 20-100-fold. Five lines of evidence suggest that this phenomenon results from binding of an IBP-Ab-Ag complex to B cells possessing IBP receptors. First, we showed that SpA is likely to boost presentation of a free mAb, suggesting that the IBP-boosted presentation of an Ag in an immune complex results from the binding of IBP to the mAb. Second, FACS® analyses showed that an Ag-Ab complex is preferentially targeted by SpA to a subpopulation of splenocytes mainly composed of B cells. Third, SpA-dependent boosted presentation of an Ag-Ab complex is further enhanced when splenocytes are enriched in cells containing SpA receptors. Fourth, the boosting effect largely diminishes when splenocytes are depleted of cells containing SpA receptors. Fifth, the boosting effect occurs only when IBP simultaneously contains a Fab and an Fc binding site. Altogether, our data suggest that soluble IBPs can bridge immune complexes to APCs containing IBP receptors, raising the possibility that during an infection process by bacteria secreting these IBPs, Ag-specific T cells may activate IBP receptor-containing B cells by a mechanism of intermolecular help, thus leading to a nonspecific immune response.
Key words: Ag presentation; protein A; B cell superantigen ![]() |
Introduction |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Previous studies have shown that an Ag-specific Ab can
modulate presentation of an Ag to T cells (1). At
least two mechanisms can be associated with these observations. First, some of the Fc receptors expressed on APCs
can mediate the internalization of the immune complex and
thus may enhance Ag presentation (6). Second, Ag-specific Abs can affect the processing pattern of an Ag (9, 10),
causing an enhanced or suppressed presentation of various
T cell determinants (11, 12). This raises the question of
whether components that interact with Abs, such as soluble microbial Ig binding proteins (IBPs),1 can also influence
presentation of Ag-Ab complexes.
Microbial IBPs are produced by protozoa, viruses, and
both gram-positive and gram-negative bacteria (13) and
play important physiological roles (14). In particular, protein A (SpA) from Staphylococcus aureus can modify opsonization, phagocytosis, complement consumption (15, 16),
Ab-dependent cell-mediated cytotoxicity (17), and mitogenesis (18). Molecular properties of SpA are well documented. It is a monomeric protein that can bind to an Ig
molecule, free or bound to its Ag (19). SpA can bind to
the Fc part of the Ab (22) through any of its five Fc
binding domains, called EDABC (23, 24). It can also bind
to the Fab region of an Ab via an alternative recognition
site (25) located in the VH domain (31). This site is
present in a large proportion of IgM, IgA, and IgG F(ab')2
that are restricted to the VHIII family in humans (32)
and to the S107 and J606 families in mice (35, 36). Thus,
SpA can interact with a large proportion of B cells and is
therefore considered a B cell superantigen (37, 38). As SpA
is naturally and efficiently secreted by S. aureus (39),
we investigated its possible influence on presentation of an
Ag-Ab complex.
In this study, we examined, in a murine model, the influence of SpA on T cell presentation of Ag-Ab complexes, using a snake toxin as a proteic Ag, two toxin-specific mAbs, splenocytes, and two Ag-specific T cell hybridomas. We show that SpA not only abolishes the capacity of mAbs to diminish Ag presentation but also increases Ag presentation by 20-100-fold. In addition, we show that (i) SpA targets Ag-Ab complex to a subpopulation of splenocytes containing SpA receptors and mainly composed of B lymphocytes; (ii) APCs that possess SpA receptors are responsible for the boosting effect; (iii) the boosting effect occurs only when the IBP simultaneously possesses a Fab and an Fc binding site; (iv) in the absence of its Ag, an Ab also undergoes a SpA-specific boosted presentation. Altogether, our observations suggest that SpA boosts Ag presentation by bridging an immune complex to SpA receptors present at the surface of appropriate APCs. We also show that protein G from Streptococcus subspecies (ssp.) group C, another bacterial IBP, can also boost presentation of Ag-Ab complexes. Our observations raise the possibility that during an infection process by bacteria secreting these IBPs, Ag-specific T cells may activate IBP receptor-containing B cells by a mechanism of intermolecular help, thus leading to a nonspecific immune response. Several reports suggest that these observations may also be extended to humans.
![]() |
Materials and Methods |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Proteins and Reagents
Protein A from S. aureus, protein G from group C Streptococcus
ssp., the IgG binding fragment BB, and protein G' were purchased from Sigma Chemical Co. ZZ was expressed and purified as previously described (49). Toxin was purified from Naja nigricollis
venom (Pasteur Institute, Paris, France). Purity of the toxin was assessed by both reverse phase HPLC and isoelectric focusing. Biorex
70 and Bio-Gel P2 were obtained from Bio-Rad Labs. N-succinimidyl-3(2-pyridyldithio) proprionate (SPDP) was purchased from
Pharmacia, and N-succinimidyl 4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) was purchased from Pierce Chemical
Co. N-hydroxysuccinimidyl-fluorescein-5(6)-carboxamidocaproate (NHS-FCC) was obtained from Sigma Chemical Co. The HPLC
C18 column (25 cm × 10 mm) was from Vydac. All solvents were
obtained from Merck and used without further purification. mAb
B220, Mac-2, anti-CD4, and anti-CD8 were from the American
Type Culture Collection. Streptavidin-PE (SAPE) was purchased
from Caltag Labs.
Chemical Modification of Proteins
Chemical Modification with NHS-FCC and NHS-biotin.
SpA was dialyzed overnight at 4°C against PBS before its modification with NHS-FCC. 52 nmol of SpA was subsequently incubated for 1 h at room temperature with 10× excess NHS-FCC. The reaction mixture was filtered through a Sephadex G15 column (26 × 1.5 cm) equilibrated in 50 mM phosphate buffer, pH 7.2. The protein that eluted in the void volume was used without further purification. 73.5 nmol of toxinCovalent Coupling of Toxin to mAb MST2
For the covalent coupling of toxin to MST2, we used a
modified procedure of the protocol previously described for coupling of toxin
to peroxidase (42).
Monothiolation of Toxin .
Incorporation of Maleimido Groups into mAb MST2.
5.5 µl of dimethylformamide containing 83 nmol of SMCC was added to 8.3 nmol of MST2 dissolved in 312 µl of 0.1 M phosphate buffer, pH 7, containing 0.1 M NaCl. The mixture was left for 1 h with stirring at room temperature. The reaction mixture was then filtered through a Sephadex G15 column (20 × 0.5 cm) equilibrated in 0.1 M phosphate buffer, pH 6, containing 0.1 M NaCl.Coupling Procedure.
The coupling reaction was performed in three steps. (i) The extra disulfide bond at Lys 27 was reduced. 8.3 nmol of the derivative was dissolved in 200 µl of 0.1 M acetate buffer, pH 4.5, containing 0.1 M NaCl and 25 mM dithiothreitol. The mixture was left under stirring at room temperature for 20 min, and the solution was filtered through a Sephadex G15 column (20 × 0.5 cm) equilibrated in 0.1 M phosphate buffer, pH 6.1, containing 0.1 M NaCl. The monothiolated toxin eluted in the void volume. (ii) (27-NELISA
Microtiter ELISA plates were coated overnight with either
0.3% BSA or polyclonal human (h) IgMs (1 µg/well) in 0.05 M
phosphate buffer, pH 7.4. Plates were then saturated with 0.3%
BSA in 0.1 M phosphate buffer, pH 7.4. Dilutions of biotinylated
toxin , M
2-3, ZZ, and BB were performed in 0.1 M phosphate buffer, pH 7.4, containing 0.1% BSA. For the assessment of
the binding of M
2-3 to IgM-coated plates, the mAb (3 nM) was
incubated overnight at 4°C in BSA-coated plates in the presence
or absence of ZZ or BB (8 nM for each SpA derivative). The incubated solutions were then transferred into IgM-coated plates
and left at room temperature for 4 h. The wells were then washed
five times with 0.01 M phosphate buffer, pH 7.4, containing
Tween 20, and a F(ab')2 goat anti-mouse IgG peroxidase conjugate (Immunotech) was added and incubated for 30 min. After extensive washings, 2,2'-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid) (ABTS) was added, coloration was developed for 30 min, and the resulting absorbance was measured at 414 nm. For the assessment of the binding of biotinylated toxin
to IgM-coated plates,
M
2-3 and biotinylated toxin
were incubated overnight at 4°C
in BSA-coated plates in the presence or absence of ZZ or BB.
The incubated solutions were then transferred into IgM-coated
plates and left at room temperature for 4 h. The wells were washed,
and a streptavidin peroxidase conjugate (Immunotech) was added
and incubated for 30 min. ABTS was used as a substrate as described above.
T Cell-stimulating Assay
All experiments were performed using DCCM1 (Biological Industries) as a synthetic culture medium, in the absence of FCS. Fixed or serial dilutions of the different Ags were preincubated in microculture wells for one night at 4°C. 5 × 105 splenocytes per well were then added, along with 5 × 104 of either T1B2 or T1C9 hybridoma. Cells were cultured for 24 h at 37°C in a humidified 7% CO2 atmosphere. For the assessment of the presenting capacity of SpA-specific cells, various amounts of splenocytes, splenocytes enriched with SpA-specific cells, or splenocytes depleted of SpA-specific cells were added to the wells in the presence of 5 × 104 T1B2.
The presence of IL-2 in culture supernatants from T cell hybridoma and bulk culture was evaluated by determining the proliferation of an IL-2-dependent cytotoxic T cell line (CTLL) using methyl [3H]TdR (5 Ci/mmol; CEA). The data are expressed in cpm.
Flow Cytometric Analysis
Binding to Splenocytes.
Biotinylated toxinCell Sorting of Splenocytes.
Cells were incubated for 30 min at 4°C in the presence of SpAF. After three washings, splenocytes were filtered through nylon and sorted at 2,000 cells/s under sterile conditions on an EPICS V flow cytometer (Coulter) using a 76-µM nozzle and the 488-nm line of an argon laser set at 300 mW. PBS was used as a sheath fluid. The sorting criteria were normal forward-angle light scatter and bright fluorescein fluorescence (515-560 nm) taken on a log scale; ~2% of cells were positive.Binding to Cell-sorted Splenocytes.
Biotinylated toxin ![]() |
Results |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
We investigated the influence of SpA from S. aureus on presentation of
an Ag-Ab complex to Ag-specific T cells. We used a snake
toxin, toxin (43), as an Ag, two toxin
-specific T cell hybridomas, called T1C9 and T1B2 (44), and two IgG2a toxin
-specific mAbs, called M
1 (45) and M
2-3 (46), whose
epitopes are topographically unrelated to each other. Serial
dilutions of toxin
were preincubated overnight at 4°C in
the presence of fixed quantities of a toxin-specific mAb (M
1
or M
2-3) and SpA before addition of the appropriate T cells
and splenocytes from BALB/c mice. Secretion of IL-2 was
determined 24 h later. As shown in Fig. 1, the capacity of
toxin
to stimulate T1B2 and T1C9 in the presence of splenocytes decreased when the Ag was incubated with either
M
1 (Fig. 1, A and B) or M
2-3 (Fig. 1 C). However, the
suppressing effect caused by the two toxin-specific mAbs not
only vanished in the presence of soluble SpA, but the efficacy
of Ag presentation dramatically increased. Fig. 1 shows that
20-100-fold lower amounts of toxin
sufficed to cause secretion of the same amounts of IL-2 when the Ag was incubated with both toxin-specific mAbs and SpA. Therefore, the
presence of an Ig-binding protein can specifically enhance
presentation of an Ag complexed to an Ag-specific Ab.
|
In these experiments, we used relatively high proportions of SpA and mAbs (0.2 µM). Nevertheless, when their concentrations decreased to 4 nM and 2 nM, respectively, being thus probably closer to physiological conditions, a potent boosting effect remained observable (Fig. 1 D). It is notable that, in these experiments, the initial suppressing effect of the mAb apparently disappeared (Fig. 1 D). This is no surprise, as the ratio of concentrations of mAb (2 nM) to antigen (0.1 µM) was low and, as a result, the presentation associated with the free toxin dominated and overshadowed the inhibiting effect of the mAb. The same phenomenon was observed in all experiments in which the toxin concentration was higher than that of the antibody (see below).
This is not the first time that an Ag presentation has been shown to be affected by mAbs. In particular, presentation of tetanus toxin was shown to increase or decrease in the presence of some specific mAbs (11, 12). In our study, we observed only a decrease in presentation by both toxin-specific mAbs, although they bound to topographically unrelated epitopes (45, 46). This result might be associated with the small size (6.8 kD) of the antigen, whose mAbs cover a large proportion of the toxin surface and are thus likely to interfere with presentation of the toxin T cell epitopes, located between residues 24-41 and 32-49 (44).
It was previously shown that when SpA is expressed at
the surface of Staphylococcus or coupled to Sepharose, it can
exert a mitogenic stimulating effect (18, 47). To rule out
the possibility that the SpA-specific boosting phenomenon
described above was related to such a nonspecific property,
various controls were performed. First, in the absence of
any mAbs, M1, or M
2-3, the toxin
stimulation efficacy was unaffected by SpA (Fig. 1, A and B). Second, in
the absence of toxin
, no IL-2 stimulation was triggered
by soluble SpA and M
1 (Fig. 1, A and B). Third, SpA did
not modify Ag presentation when the Ab was an unrelated IgG2a (Fig. 1 D). Fourth, no stimulation occurred when
splenocytes and T1B2 were incubated separately with SpA,
toxin
, and M
1 (data not shown). Therefore, besides the
necessary appropriate immune cells, three additional components were absolutely required for the boosting effect to
be observable: the Ag, an Ag-specific Ab, and soluble SpA.
The presentation of free toxin to T1B2 and
T1C9 is restricted to I-Ad and I-Ed, respectively (44). We
investigated whether or not this MHC restriction was still
associated with the SpA-boosted presentation of the toxin
using splenocytes from D2GD mice, which express I-Ad
and I-Eb molecules. We observed that the capacity of toxin
to stimulate T1B2 was boosted when the toxin was added
concomitantly with both the mAb and SpA (Fig. 2 A),
whereas under the same experimental conditions, T1C9 was
not stimulated (Fig. 2 B). Therefore, the SpA-dependent
boosting presentation of an Ag complexed to an Ag-specific Ab remains MHC restricted and is not related to the MHC-independent genetic background of BALB/c mice.
|
What are the mechanisms that may account for an
SpA-dependent boosting presentation of an Ag complexed
to an Ag-specific Ab? As already mentioned, SpA possesses
multiple Ig binding sites (23, 24) and therefore could bind
simultaneously to several immune complexes, thus generating an artificial concentration effect. In other words, incubation of stoichiometric concentrations of Ab and SpA could
favor formation of heterogeneous multimolecular complexes, and those possessing several toxin molecules could predominantly generate the boosting effect. To examine
such a possibility, we incubated overnight a constant concentration of SpA with varying dilutions of toxin and
either a fixed concentration of M
1 or varying concentrations of M
1 so that the ratios of SpA/M
1 were equal to
1.5, 4.5, 13.5, 40.5, 121.5, or 364.5 for the first to the sixth
dilution, respectively. Thus, in each toxin dilution, at most
one molecule of the immune complex should have bound
to one SpA molecule. As shown in Fig. 3, T cell presentation evolved similarly with toxin dilution, irrespective of
whether the concentrations of M
1 were fixed or variable.
Therefore, the observed boosted T cell stimulation seems
to be unrelated to the number of Ab-Ag molecules associated to an SpA molecule.
|
Another explanation that may account for the SpA-
enhanced presentation of an Ag is that SpA targets Ag-Ab
complexes to APCs that possess SpA receptors on their surfaces. To investigate this possibility, we performed a series
of FACS® analyses. At first, we examined the direct binding
of SpA to splenocytes using SpA labeled with FCC (SpAF).
As shown in Fig. 4, E-G, labeled SpA binds specifically to a
subpopulation of splenocyte cells. We then investigated the
binding of the Ag on splenocytes using SpA, a toxin-specific mAb (M1), and the biotinylated toxin
, which was detected by SAPE. When the biotinylated toxin
was added
alone, <0.5% of splenocytes were labeled (Fig. 4 A). The same result was obtained when SpA (Fig. 4 B) or M
1 (Fig.
4 C) was added separately. In sharp contrast, when the biotinylated toxin was concomitantly incubated with M
1
and SpA, the proportion of labeled cells increased to nearly
3% (Fig. 4 D). These findings support the view that splenocytes possess SpA-specific cells and that an Ag-Ab complex
binds to this subpopulation.
|
To further validate this conclusion, we sorted SpAF-
labeled splenocytes (2% of the whole population) and investigated the binding of the biotinylated Ag to this population enriched in SpA-specific cells. 32% of the positively
sorted splenocytes were effectively labeled with SpAF (Fig.
5 E, bottom right). In the absence of both SpA and M1,
quite a small proportion of these cells were labeled with the
biotinylated toxin (Fig. 5 E, top right). In contrast, when
both M
1 and SpA were present, nearly 60% of the SpAF-labeled cells were labeled with the biotinylated Ag (Fig. 5 F,
top right). However, a proportion of SpAF-labeled splenocytes were not labeled with the biotinylated toxin, even when both the mAb and SpA were present in the medium
(Fig. 5 F, bottom right). No definite explanation presently
accounts for this observation. Control experiments were
carried out with the population of negatively sorted cells,
which contained only 0.4% of SpAF-labeled cells (Fig. 5 C,
bottom right). Only 0.6% of the depleted splenocytes were
labeled with the biotinylated Ag in the presence of the Ab
and SpA (Fig. 5 D, top left and top right), and this value
did not increase to more than 2.5% when the splenocytes were unsorted (Fig. 5 B, top left). Altogether, these experiments provide direct evidence that in the presence of SpA,
an Ag-Ab complex is preferentially targeted to a particular
subpopulation of splenocytes that possess SpA receptors.
|
To identify the cell types that predominantly populated splenocytes enriched in sorted SpAF-labeled cells, we used four biotinylated mAbs (mAb B220, mAb Mac 2, mAb GK1.2, and mAb H35) and SAPE. As shown in Fig. 5 G, a shift in fluorescence intensity was observed with the B cell marker, whereas no shift was observed using macrophage, CD4, and CD8 cell surface markers (Fig. 5, H-J). Therefore, SpAF-bound cells are mainly composed of B cells.
The Boosted Presentation Requires APCs Possessing SpA Receptor.We investigated the ability of both unsorted splenocytes (S) and splenocytes enriched with (ES) or depleted
of (DS) SpAF-bound cells to stimulate T1B2 in the presence of toxin alone or in combination with both SpA and
M
1. As shown in Fig. 6 A, 104 splenocytes enriched with
SpA receptor-possessing cells were ~10-fold more efficient
than 104 unsorted splenocytes at boosting toxin
presentation in the presence of M
1 and SpA. In contrast, 105 unsorted splenocytes were ~10-fold more efficient than 105
splenocytes depleted of SpA receptor-containing cells (Fig.
6 B). The observed differences in efficiency are not related to a modification of the processing efficiency of cells treated
with SpAF during the sorting experiments, as control experiments showed that splenocytes enriched with SpA receptor-containing cells were equally as efficient as unsorted
splenocytes at presenting toxin
alone (Fig. 6). Further
demonstration that positively sorted cells are more efficient
than unsorted cells, which in turn are more efficient than
the negatively sorted splenocytes, is also shown in Fig. 6 C,
where stimulation of T1B2 by the Ab-Ag complex in the
presence of SpA is shown as a function of the number of cells. Therefore, the subpopulation of splenocytes possessing SpA receptors is mainly responsible for the capacity of
SpA to boost the T cell stimulation of Ag-Ab complex.
|
The above
data indicated that the Ag-Ab complexes are targeted to
SpA receptors present at the surface of APCs containing predominantly B cells. In other words, the boosting effect
can be interpreted as resulting from the formation of complexes that consist of a SpA receptor bound to SpA, which
in turn is bound to Ab-Ag complex. To investigate the
possibility that the SpA receptors may be surface Igs, we
proceeded as follows. First, we selected two SpA derivatives which differ in their recognition specificity toward
Igs. One of them is composed of two B domains (BB), and,
like SpA, recognizes the Fab region of IgMs and IgGs as
well as the Fc part of IgG (48). The other derivative is ZZ
(Z is a mutant of domain B [49]) and binds to the Fc
part of IgG but very weakly to the Fab region (50). Second, we
examined the binding of either a mouse mAb or biotinylated toxin
to hIgM-coated plates. As shown in Fig. 7 A
(left), the mouse IgG2a mAb M
2-3 can bind to coated
hIgMs in the presence of BB but not in the presence of
ZZ. Furthermore, the presence of M
2-3 and BB is a prerequisite for the binding of biotinylated toxin
to coated hIgMs (Fig. 7 A, right). Therefore, formation of a ternary
complex, IgM-SpA derivative-IgG, or a quaternary complex, IgM-SpA derivative-IgG-Ag, is possible, provided
that the derivative can bind to both IgG and IgM. In addition, the VH domain of M
2-3 is coded by the VH germline
gene J558 (51), a characteristic that precludes the Fab of this
IgG to bind SpA and BB (35, 36). As a result, this IgG can be
recognized only through its Fc
. Therefore, the complex
observed in the ELISA consists of an IgM bound by its Fab
to BB, which in turn binds to the Fc
region of M
2-3.
|
Third, we investigated the effect of the two SpA derivatives on the labeling of splenocytes from BALB/c mice by a
mouse IgG-FITC. In these unpublished experiments, we
observed that 10.8% of the splenocytes were bound by the
mouse IgG2a-FITC, a proportion which increased to
23.8% in the presence of BB and decreased to 6.4% in the
presence of ZZ. Fourth, we investigated the capacity of BB
and ZZ to boost the presentation of the M2-3-toxin
complex using T1C9 and splenocytes. As shown in Fig. 7
B, a boosting effect is observed when the Ab-Ag complex
is incubated in the presence of BB but not in the presence
of ZZ. Thus, the boosting effect requires that the SpA derivative possesses both a binding site to the Fc
region of
M
2-3 and a binding site to the Fab of Igs, strongly suggesting that the BB-M
2-3-Ag complex is targeted to the
Fab region of surface Igs of APCs.
We investigated whether a bacterial IBP other
than SpA could also trigger a boosting effect. Several of the
above experiments were therefore repeated using protein G
from Streptococcus ssp. group C (52), which contains both a
Fab binding site and an Fc binding site (53, 54). As shown
in Fig. 8 A, protein G boosted presentation of toxin
to
T1B2 only when the toxin, M
2-3, and protein G were
concomitantly added to appropriate immune cells. In contrast, the boosting effect was not observed with protein G',
a protein G derivative that binds exclusively to the Fc
of Igs (55). Therefore, these data suggest that the boosted presentation of an Ab-Ag complex results from a targeting by
protein G to the Fab region of surface Igs of APCs. This
raises the question of whether SpA and protein G recognize
the same APC subpopulation. To approach this question,
we performed FACS® analyses using both biotinylated protein G and SpAF. As shown in Fig. 8, protein G (B3, top left)
and SpAF (B2, bottom right) bind to approximately the
same proportion of the whole splenocyte population. Furthermore, the data presented in Fig. 8 (B4) suggest that SpA
and protein G may recognize different splenocyte subpopulations. However, as we observed a slight increase in the upper right area of B4, we cannot preclude that a proportion of
cells recognized by SpA and protein G are the same.
|
The view that emerges from the above data is that presentation of an Ag is boosted in the presence of an Ag-specific
Ab as a result of the targeting of the complex by an IBP to
APCs that contain IBP receptors. According to this scenario,
both the mAb and SpA should also undergo a boosted presentation. This was demonstrated earlier to be the case for
SpA (56). To provide evidence that it is also the case for
the mAb, one would need mAb-specific T cells; however,
they were unavailable in our laboratory. To overcome this
difficulty, we used the toxin -specific T1B2 to tentatively monitor the presentation of an mAb that was selected for
its inability to recognize toxin
(57). This mAb, an IgG1
called MST2, was covalently linked to toxin
, which became, therefore, a label to probe the presentation of MST2.
As shown in Fig. 9, the MST2-toxin
couple was efficiently presented to T1B2, and its presentation was clearly
boosted by SpA. As a control, no such boosting effect was
observed when the free toxin
was incubated with both
the uncoupled MST2 and SpA (not shown). Therefore,
only the toxin that was covalently linked to the Ab underwent a boosted presentation. This effect most probably reflects a boosting effect of the Ab itself. We conclude, therefore, that the boosting presentation of an Ab-Ag complex,
as previously perceived via the stimulation of the Ag, reflects an increased presentation of both the Ag and Ag-specific Ab, a finding in agreement with the proposed scenario that an immune complex may be targeted by SpA to APC
containing SpA receptors.
|
![]() |
Discussion |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
Using a snake toxin as an Ag and two toxin-specific
mAbs (M1 and M
2-3), we showed that two soluble
bacterial IBPs, SpA and protein G, dramatically increase the
Ag-specific T cell stimulation of Ag-Ab complex. These
findings are in sharp contrast to the observation that, in the
absence of IBP, either of the Ag-specific mAbs inhibits presentation of the Ag.
A number of observations cast some light on the origin of this IBP-dependent boosting phenomenon. Thus, for the boosted presentation of the Ag to be seen, the Ag, an Ag-specific Ab, and an IBP, SpA or protein G, are absolutely required. As SpA is likely to boost presentation of a free Ab, we propose that the SpA-dependent boosted presentation of an immune complex, as perceived through presentation of its Ag, results from the binding of SpA to the Ab of the immune complex. Three lines of evidence indicate that the Ag-boosted presentation may result from binding of a ternary complex SpA-Ab-Ag to B cells containing SpA receptors. First, FACS® analyses demonstrated that an Ag-Ab complex is preferentially targeted by SpA to a subpopulation of splenocytes possessing SpA-specific receptors and mainly composed of B cells. Second, the boosted presentation further increased when splenocytes were enriched in cells containing SpA-specific receptors. Third, the boosting effect largely decreased when APCs were depleted of cells containing SpA-specific receptors. Altogether, these observations suggest that the two soluble IBPs can bridge an immune complex to IBP receptors present at the surface of a particular subpopulation of APCs, thus enhancing endocytosis and presentation of the Ag.
For SpA to bridge an immune complex to SpA receptors, appropriate binding sites must exist on the Ag-Ab
complex. It is known that SpA can interact with the Fc
region of mouse IgGs without impairing the binding of the
Ags to their paratopes (19). In addition, SpA can bind to an
alternative site located within the Fab domain of some mouse
Igs (25, 29) that is coded by VH families S107 or J606 (35,
36). The VH domain of M
2-3, one of the two toxin-specific mAbs that triggered the boosting effect, is coded by the
VH germline gene J558 (51), whose gene product is, therefore, not recognized by SpA (35, 36). Thus, the Fc
region
of M
2-3 and perhaps of M
1, whose amino acid sequence is still unknown, are likely to be responsible for the interaction of the immune complex with SpA.
For SpA to bridge the Ab-Ag complexes to APCs, these
cells must also possess appropriate SpA receptors. Four lines
of evidence suggest that these receptors are surface Igs and
most probably IgMs. First, we observed that the quaternary
complex IgM-SpA (or BB)-M2-3-Ag can occur in vitro.
Second, binding of a soluble IgG to splenocytes is increased
only in the presence of an IBP derivative that possesses the
capacity of binding concomitantly to Fab and Fc
moieties.
Third, for the boosting effect to be observed, an IBP with
the same characteristics is also strictly required. Fourth, SpA
preferentially targets Ab-Ag complex to a subpopulation of
B cells. Because the surface IgMs offer an alternative binding
site on the Fab domain, we suggest that they constitute the
most plausible SpA receptors. Other possible SpA receptors
are the Igs bound in vivo to FcRs present at the surfaces of
macrophages (58). Although we detected no macrophages
in the subpopulation of splenocytes enriched in cells containing SpA receptor, we cannot rule out their participation
in the boosting effect. Therefore, our findings are compatible with the view that SpA may link the Fc
part of the Ab
moiety of an immune complex to cell surface, SpA-specific
receptor structures such as IgMs present at the surface of a
subpopulation of murine splenocytes.
Protein G from Streptococcus ssp. also efficiently boosts the
presentation of Ag in immune complexes. Like SpA, protein G binds to the Fc region of IgGs in the C2-C
3
interface (53, 54), their respective epitopes partially overlapping (59). Unlike SpA, however, protein G binds to Fab
regions of IgG via the CH1 domain (60, 61) and not to
IgMs (52). Therefore, if soluble protein G acts, like SpA, as
an enhancer of immune complex presentation, its bridging
capacity is likely to be different. Presumably, protein G predominantly focuses immune complexes to APCs carrying IgGs.
Several lines of evidence, mostly taken from the literature, indicate that SpA may react similarly with both human and mouse Igs. First, hIgs bind at two independent sites on SpA (14, 26, 30). Second, mouse Igs S107 and J606 are related to the human VH genes of family 3 (62), and several works have shown that hIgG F(ab')2 and hIgM reacting with SpA derive from the VHIII family but do not have markers for other families (32). More precisely, 16/26 potentially functional germline VHIII genes encode SpA reactivity (63, 64). Third, SpA-Sepharose or SpA-containing S. aureus can stimulate B cells expressing VH gene segments encoded by a set of genes belonging to the VHIII family (47). Fourth, as reported above, the quaternary complex hIgM-SpA-mAb-toxin is sufficiently stable to be detected in ELISA assays. Plausibly, therefore, soluble SpA could bridge the Fc region of soluble hIgs to cell surface hIgs coded by one or more of the 16 germline VHIII genes encoding SpA reactivity. Remarkably, up to 54% of human B cells are capable of binding SpA (64), whereas VH families J606 and S107 are expressed in only 10-20% of adult B lymphocytes of BALB/c mice (65) and are likely to bind SpA. Therefore, it is not impossible that the binding of SpA with hIgs could cause a boosting effect in humans similar to the one that we described here for mice.
During an humoral immune response, an Ag is captured
by dendritic cells, macrophages, and Ag-specific B cells,
processed, and presented to Ag-specific T helper cells.
This cascade of events leads to Ab secretion. The secreted
Ag-specific Abs bind to the Ag, forming an heterogeneous
population of immune complexes. It has been proposed
that these complexes can cause a negative feedback on the
specific antibody response, as a result of the diversion of
Ags from their specific B cells, toward cells possessing Ig receptors, i.e., FcR-expressing cells and RF-producing B
cells (69). In this scenario, the Ag-specific helper T cells
may activate B cells producing RF by intermolecular help.
The data presented in this paper suggest another mechanism that might affect the immune response during an infection process by IBP-secreting bacteria. As a result of the
presence of a soluble IBP, SpA for example, the Ab-Ag
complexes may be targeted to B cell IgMs that can bind SpA. The SpA-binding B cells may thus present T cell
epitopes from the targeted immune complexes and stimulate the corresponding T cells and may be activated by an
intermolecular help mechanism. Although their specific
Ags may not necessarily be present in the medium, the targeted B cells may nevertheless secrete their natural antibodies. The specificities of the produced antibodies cannot be
identified a priori. However, they are likely to be large because the VH-reactive B cells are not bound by SpA via the
traditional antigen binding site. It is tempting to speculate that this predicted diverting mechanism by an IBP may
help the bacteria to evade the immune response.
![]() |
Footnotes |
---|
Address correspondence to Michel Léonetti, Département d'Ingénierie et d'Etudes des Protéines (DIEP) CEA/Saclay, 91191 Gif-sur-Yvette cedex, France. Phone: 33-1-69-08-64-56; Fax: 33-1-69-08-90-71; E-mail: leonetti{at}cea.fr
Received for publication 29 June 1998 and in revised form 30 December 1998.
J. Galon was a recipient of fellowships from Ministère de la Recherche and of Association de Recherche contre le Cancer.We are indebted to the Service de Cytométrie, Institut des Sciences Végétales, Centre Nationale de la Recherche Scientifique-Unité de Recherche Propre 040, 91198 Gif-sur-Yvette, France, where we performed
our cell sorting experiments. We gratefully acknowledge Dr. Pascal Kessler for providing us with monothiolated toxin and Dr. Gilles Mourier for providing us with the NH2-terminally biotinylated toxin
.
Abbreviations used in this paper CTLL, cytotoxic T cell line; FCC, fluorescein-5(6)-carboxamidocaproic; hIg, human immunoglobulin; IBP, immunoglobulin binding protein; SAPE, streptavidin-PE; SpA, staphylococcal protein A; ssp., subspecies.
![]() |
References |
---|
![]() ![]() ![]() ![]() ![]() ![]() ![]() |
---|
1. | Celis, E., and T.W. Chang. 1984. Antibodies to hepatitis B surface antigen potentiate the response of human T lymphocyte clones to the same antigen. Science. 224: 297-299 [Medline]. |
2. | Celis, E., V.R. Zurawski Jr., and T.W. Chang. 1984. Regulation of T-cell function by antibodies: enhancement of the response of human T-cell clones to hepatitis B surface antigen by antigen-specific monoclonal antibodies. Proc. Natl. Acad. Sci. USA. 81: 6846-6850 [Abstract]. |
3. | Corradin, G., and H.D. Engers. 1984. Inhibition of antigen-induced T-cell clone proliferation by antigen-specific antibodies. Nature. 308: 547-548 [Medline]. |
4. |
Corradin, G.,
M.A. Juillerat, and
H.D. Engers.
1984.
Differential effects of two anti-apo-cytochrome c-specific monoclonal antibodies on the function of apo-cytochrome c-specific murine T cell clones.
J. Immunol.
133:
2915-2919
|
5. |
Schalke, B.C.,
W.E. Klinkert,
H. Wekerle, and
D.S. Dwyer.
1985.
Enhanced activation of a T cell line specific for acetylcholine receptor (AChR) by using anti-AChR monoclonal
antibodies plus receptors.
J. Immunol.
134:
3643-3648
|
6. | Amigorena, S., C. Bonnerot, J.R. Drake, D. Choquet, W. Hunziker, J.-G. Guillet, P. Webster, C. Sautès, I. Mellman, and W.H. Fridman. 1992. Cytoplasmic domain heterogeneity and functions of IgG Fc receptors in B lymphocytes. Science 256: 1808-1812 [Medline]. |
7. | Amigorena, S., J. Salamero, J. Davoust, W.H. Fridman, and C. Bonnerot. 1992. Tyrosine containing motif that transduces cell activation signals also determines internalization and antigen presentation via type III receptors for IgG. Nature 358: 337-341 [Medline]. |
8. |
Amigorena, S.,
D. Lankar,
V. Briken,
L. Gapin,
M. Viguier, and
C. Bonnerot.
1998.
Type II and III receptors for immunoglobulin G (IgG) control the presentation of different T
cell epitopes from single IgG-complexed antigens.
J. Exp.
Med.
187:
505-515
|
9. |
Manca, F.,
D. Fenoglio,
A. Kunkl,
C. Cambiaggi,
M. Sasso, and
F. Celada.
1988.
Differential activation of T cell clones
stimulated by macrophages exposed to antigen complexed
with monoclonal antibodies. A possible influence of paratope
specificity on the mode of antigen processing.
J. Immunol.
140:
2893-2898
|
10. | Davidson, H.W., and C. Watts. 1989. Epitope-directed processing of specific antigen by B lymphocytes. J. Cell Biol. 109: 85-92 [Abstract]. |
11. | Watts, C., and A. Lanzavecchia. 1993. Suppressive effect of antibody on processing of T cell epitopes. J. Exp. Med. 178: 1459-1463 [Abstract]. |
12. | Simitsek, P.D., D.G. Campbell, A. Lanzavecchia, N. Fairweather, and C. Watts. 1995. Modulation of antigen processing by bound antibodies can boost or suppress class II major histocompatibility complex presentation of different T cell determinants. J. Exp. Med. 181: 1957-1963 [Abstract]. |
13. | Widders, P.R. 1990. Fc receptors and the pathogenesis of bacterial infections in animals. In Bacterial Immunoglobulin-binding Proteins, Vol. 1. M.D.P. Boyle, editor. Academic Press, Inc., Orlando, FL. 375-396. |
14. | Langone, J.J.. 1982. Protein A of Staphylococcus aureus and related immunoglobulin receptors produced by streptococci and pneumococci. Adv. Immunol 32: 157-252 [Medline]. |
15. | Ghetie, V., G. Mota, M.A. Dobre-Ghetie, M. Laky, A. Olinescu, S. Dima, I. Moraru, and J. Sjoquist. 1986. Modulation of IgG effector functions by a monovalent fragment of staphylococcal protein A. Mol. Immunol 23: 377-384 [Medline]. |
16. | Kozlowski, L.M., A.M. Soulika, G.J. Silverman, J.D. Lambris, and A.I. Levinson. 1996. Complement activation by a B cell superantigen. J. Immunol. 157: 1200-1206 [Abstract]. |
17. | Rosenblatt, J., P.M. Zeltzer, J. Portaro, and R.C. Seeger. 1977. Inhibition of antibody-dependent cellular cytotoxicity by protein A from Staphylococcus aureus. J. Immunol 118: 981-985 [Abstract]. |
18. |
Romagnani, S.,
M.G. Giudizi,
G. Del Prete,
E. Maggi,
R. Biagiotti,
F. Almerigogna, and
M. Ricci.
1982.
Demonstration on protein A of two distinct immunoglobulin-binding
sites and their role in the mitogenic activity of Staphylococcus
aureus Cowan I on human B cells.
J. Immunol
129:
596-602
|
19. | Langone, J.J.. 1978. [125I] protein A: a tracer for general use in immunoassay. J. Immunol. Methods. 24: 269-285 [Medline]. |
20. | Endresen, C.. 1979. The binding to protein A of immunoglobulin G and of Fab and Fc fragments. Acta. Pathol. Microbiol. Scand. Sect. C. Immunol. 87: 185-189 . |
21. | Zikan, J.. 1980. Interactions of pig Fab gamma fragments with protein A from Staphylococcus aureus. Folia Microbiol. (Praha). 25: 246-253 [Medline]. |
22. | Deisenhofer, J.. 1981. Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-Å resolution. Biochemistry 20: 2361-2370 [Medline]. |
23. |
Uhlén, M.,
B. Guss,
B. Nilsson,
S. Gatenbeck,
L. Philipson, and
M. Lindberg.
1984.
Complete sequence of the staphylococcal gene encoding protein A. A gene evolved through
multiple duplications.
J. Biol. Chem.
259:
1695-1702
|
24. | Moks, T., L. Abrahmsen, B. Nilsson, U. Hellman, J. Sjöquist, and M. Uhlén. 1986. Staphylococcal protein A consists of five IgG-binding domains. Eur. J. Biochem. 156: 637-643 [Abstract]. |
25. | MacKenzie, M.R., G.A. Gutman, and N.L. Warner. 1978. The binding of murine IgM to staphylococcal A protein. Scand. J. Immunol 7: 367-370 [Medline]. |
26. | Inganäs, M., S.G.O. Johansson, and H.H. Bennich. 1980. Interaction of human polyclonal IgE and IgG from different species with protein A from Staphylococcus aureus: demonstration of protein-A-reactive sites located in the Fab'2 fragment of human IgG. Scand. J. Immunol 12: 23-31 [Medline]. |
27. | Inganäs, M.. 1981. Comparison of mechanisms of interaction between protein A from Staphylococcus aureus and human monoclonal IgG, IgA and IgM in relation to the classical Fc gamma and the alternative F(ab')2 epsilon protein A interactions. Scand. J. Immunol 13: 343-352 [Medline]. |
28. | Biguzzi, S.. 1982. Fc gamma-like determinants on immunoglobulin variable regions: identification by staphylococcal protein A. Scand. J. Immunol 15: 605-618 [Medline]. |
29. |
Young, W.W. Jr.,
Y. Tamura,
D.M. Wolock, and
J.W. Fox.
1984.
Staphylococcal protein A binding to the Fab fragments
of mouse monoclonal antibodies.
J. Immunol.
133:
3163-3166
|
30. |
Vidal, M.A., and
F.P. Conde.
1985.
Alternative mechanism
of protein A-immunoglobulin interaction: the VH-associated
reactivity of a monoclonal human IgM.
J. Immunol
135:
1232-1238
|
31. | Reichmann, L., and J. Davies. 1995. Backbone assignment, secondary structure and protein A binding of an isolated, human antibody VH domain. J. Biomol. NMR 6: 141-152 [Medline]. |
32. |
Sasso, E.H.,
G.J. Silverman, and
M. Mannik.
1989.
Human
IgM molecules that bind staphylococcal protein A contain
VHIII H chains.
J. Immunol
142:
2778-2783
|
33. |
Sasso, E.H.,
G.J. Silverman, and
M. Mannik.
1991.
Human
IgA and IgG F(ab')2 that bind to staphylococcal protein A
belong to the VHIII subgroup.
J. Immunol
147:
1877-1883
|
34. |
Sasano, M.,
D.R. Burton, and
G.J. Silverman.
1993.
Molecular selection of human antibodies with an unconventional
bacterial B cell antigen.
J. Immunol
151:
5822-5839
|
35. |
Seppälä, I.,
M. Kaartinen,
S. Ibrahim, and
O. Mäkelä.
1990.
Mouse Ig coded by VH families S107 or J606 bind to protein
A.
J. Immunol
145:
2989-2993
|
36. | Ibrahim, S., M. Kaartinen, I. Seppälä, A. Matoso-Ferreira, and O. Makela. 1993. The alternative binding site for protein A in the Fab fragment of immunoglobulins. Scand. J. Immunol 37: 257-264 [Medline]. |
37. | Silverman, G.J.. 1992. Human antibody responses to bacterial antigens: studies of a model conventional antigen and a proposed model B cell superantigen. Int. Rev. Immunol 9: 57-78 [Medline]. |
38. | Silverman, G.J.. 1997. B-cell superantigens. Immunol. Today 18: 379-386 [Medline]. |
39. | Forsgren, A.. 1969. Protein A from Staphylococcus aureus. VIII. Production of protein A by bacterial and L-forms of S. aureus. Acta. Pathol. Microbiol. Scand 75: 481-490 [Medline]. |
40. | Forsgren, A.. 1970. Significance of protein A production by Staphylococci. Infect. Immun. 5: 672-673 . |
41. | Movitz, J.. 1976. Formation of extracellular protein A by Staphylococcus aureus. Eur. J. Biochem 68: 291-299 [Abstract]. |
42. |
Léonetti, M.,
L. Pillet,
B. Maillère,
H. Lamthanh,
P. Frachon,
J. Couderc, and
A. Ménez.
1990.
Immunization with a
peptide having both T cell and conformationally restricted B
cell epitopes elicits neutralizing antisera against a snake neurotoxin.
J. Immunol
145:
4214-4221
|
43. | Ménez, A., L. Pillet, M. Léonetti, F. Bontems, and B. Maillère. 1992. Snake toxins as antigens. In Structure of Antigens, Vol. 1. M.H.V. Van Regenmortel, editor. CRC Press, Boca Raton, FL. 293-320. |
44. |
Maillère, B.,
J. Cotton,
G. Mourier,
M. Léonetti,
S. Leroy, and
A. Ménez.
1993.
Role of thiols in the presentation of a
snake toxin to murine T cells.
J. Immunol
150:
5270-5280
|
45. | Boulain, J.C., and A. Ménez. 1982. Neurotoxin-specific immunoglobulins accelerate dissociation of the neurotoxin-acetylcholine receptor complex. Science. 217: 732-733 [Medline]. |
46. | Trémeau, O., J.C. Boulain, J. Couderc, P. Fromageot, and A. Ménez. 1986. A monoclonal antibody which recognized the functional site of snake neurotoxins and which neutralizes all short chain variants. FEBS Lett 208: 236-240 [Medline]. |
47. |
Kristiansen, S.V.,
V. Pascual, and
P.E. Lipsky.
1994.
Staphylococcal protein A induces biased production of Ig by VH3-expressing B lymphocytes.
J. Immunol.
153:
2974-2982
|
48. | Jansson, B., M. Uhlen, and P.A. Nygren. 1998. All individual domains of staphylococcal protein A show Fab binding. FEMS Immunol. Med. Microbiol. 20: 69-78 [Medline]. |
49. | Nilsson, B., T. Moks, B. Jansson, L. Abrahmsén, A. Elmblad, E. Holmgren, C. Henrichson, T.A. Jones, and M. Uhlén. 1987. A synthetic IgG-binding domain based on staphylococcal protein A. Protein. Eng. 2: 107-113 . |
50. | Ljundberg, U.K., B. Jansson, U. Niss, R. Nilsson, B.E. Sandberg, and B. Nilsson. 1993. The interaction between different domains of staphylococcal protein A and human polyclonal IgG, IgA, IgM, and F(ab')2: separation of affinity from specificity. Mol. Immunol. 30: 1279-1285 [Medline]. |
51. |
Ducancel, F.,
K. Mérienne,
C. Fromen-Romano,
O. Trémeau,
L. Pillet,
P. Drevet,
S. Zinn-Justin,
J.-C. Boulain, and
A. Ménez.
1996.
Mimicry between receptors and antibodies. Identification of snake toxin determinants recognized
by the acetylcholine receptor and an acetylcholine receptor-mimicking monoclonal antibody.
J. Biol. Chem.
271:
31345-31353
|
52. | Björck, L., and G. Kronvall. 1984. Purification and some properties of streptococcal protein G, a novel IgG-binding reagent. J. Immunol 2: 969-974 . |
53. | Erntell, M., E.B. Myhre, U. Sjöbring, and L. Björck. 1988. Streptococcal protein G has affinity for both Fab- and Fc-fragments of human IgG. Mol. Immunol 25: 121-126 [Medline]. |
54. | Woof, J.M., and D.R. Burton. 1990. The nature of the interaction of bacterial Fc receptors and IgG. In Bacterial Immunoglobulin-binding Proteins, Vol. 1. M.D.P. Boyle, editor. Academic Press, Inc., Orlando, FL. 305-316. |
55. | Goward, C.R., J.P. Murphy, T. Atkinson, and D.A. Barstow. 1990. Expression and purification of a truncated recombinant streptococcal protein G. Biochem. J. 267: 171-177 [Medline]. |
56. |
Léonetti, M.,
R. Thai,
J. Cotton,
S. Leroy,
P. Drevet,
F. Ducancel,
J.-C. Boulain, and
A. Ménez.
1998.
Increasing immunogenicity of antigens fused to Ig binding proteins by
cell-surface targeting.
J. Immunol.
160:
3820-3827
|
57. | Charpentier, I., L. Pillet, E. Karlsson, J. Couderc, and A. Ménez. 1990. Recognition of the acetylcholine receptor binding site of a long-chain neurotoxin by toxin-specific monoclonal antibodies. J. Mol. Recognit 3: 74-81 [Medline]. |
58. | Cohen, B.E., A.S. Rosenthal, and W.E. Paul. 1973. Antigen-macrophage interaction. II. Relative roles of cytophilic antibody and other membrane sites. J. Immunol 111: 820-828 [Medline]. |
59. | Tashiro, M., and G.T. Montelione. 1995. Structures of bacterial immunoglobulin-binding domains and their complexes with immunoglobulins. Curr. Opin. Struct. Biol 5: 471-481 [Medline]. |
60. | Derrick, J.P., and D.B. Wigley. 1992. Crystal structure of a streptococcal protein G domain bound to an Fab fragment. Nature. 359: 752-754 [Medline]. |
61. | Derrick, J.P., and D.B. Wigley. 1994. The third IgG-binding domain from streptococcal protein G. An analysis by X-ray crystallography of the structure alone and in a complex with Fab. J. Mol. Biol 243: 906-918 [Medline]. |
62. | Rathbun, G., J. Berman, G. Yancopoulos, and F.W. Alt. 1989. Organization and expression of the mammalian heavy-chain variable-region locus. In Immunoglobulin Genes. T. Honjo, F.W. Alt, and T.H. Rabbits, editors. Academic Press, Inc., Orlando, FL. 63-90. |
63. | Hillson, J.L., N.S. Karr, I.R. Oppliger, M. Mannik, and E.H. Sasso. 1993. The structural basis of germline-encoded VHIII immunoglobulin binding to staphylococcal protein A. J. Exp. Med 178: 331-336 [Abstract]. |
64. | Hakoda, M., N. Kamatani, S. Hayashimoto-Kurumada, G.J. Silverman, H. Yamanaka, C. Terai, and S. Kashiwazaki. 1996. Differential binding avidities of human IgM for staphylococcal protein A derive from specific germ-line VH3 gene usage. J. Immunol 157: 2976-2981 [Abstract]. |
65. |
Silverman, G.J.,
M. Sasano, and
S.B. Wormsley.
1993.
Age-associated changes in binding of human B lymphocytes to a
VHIII-restricted unconventional bacterial antigen.
J. Immunol
151:
5840-5855
|
66. | Wu, G.E., and C.J. Paige. 1986. VH gene family utilization in colonies derived from B and pre-B cells detected by the RNA colony blot assay. EMBO (Eur. Mol. Biol. Organ.) J. 5: 3475-3481 [Abstract]. |
67. | Jeong, H.D., and J.M. Teale. 1988. Comparison of the fetal and adult functional B cell repertoires by analysis of VH gene family expression. J. Exp. Med 168: 589-603 [Abstract]. |
68. | Yancopoulos, G.D., B.A. Malynn, and F.W. Alt. 1988. Developmentally regulated and strain-specific expression of murine VH gene families. J. Exp. Med 168: 417-435 [Abstract]. |
69. | Roosnek, E., and A. Lanzavecchia. 1991. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J. Exp. Med. 173: 487-489 [Abstract]. |